Injections are a common method of injecting drugs into a patient to prevent or cure diseases. However, it is an invasive mode of drug administration as it causes tissue damage. Moreover, injections can cause the transmission of diseases, especially when needles are repeated or used incorrectly. To get rid of these obstacles, the needle-free injection technology (NFIT) was developed. It has gained enormous popularity in the past few years due to its potential of making the administration of drugs more efficient, safe, less expensive, and convenient.
Its additional benefits include faster injection compared with traditional needles and no issues of disposal of needles. The technology is a concept encompassing a range of drug delivery systems that drives drugs through the skin using forces such as Lorentz, Shock waves, pressure by gas, or electrophoresis. Besides the pharma industry, NFIT is also beneficial for the developing world for its application in mass immunization programs, nullifying the cases of needle stick accidents and other complications. Some of the emerging applications of NFI include its use in the treatment of diabetes, hemophilia, and in giving local anesthetics. Variants of this technology which are being marketed include Bioject ZetaJetTM, Vitajet 3, Tev-Tropin and others.
Today, the needle-free injection technology is developing steadily and holds the promise of making the administration of drugs more efficient and less painful in the coming years. In a report by Allied Market Research, the global needle-free injections systems market is likely to reach $23,116 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Several factors are positively influencing the industry growth such as the elimination of the risks associated with needles, reduction of healthcare costs, the rise in the incidence of diseases, and the improved immune response to vaccines. However, lack of skilled professionals and the prohibited use of needle-free injections for intravenous administration are major restraints of the market growth.
Several companies are involved in the development of the NFIT technology. Apart from developing technologies that are safer and easier to use, they are also working on alternatives which can deliver more types of medicines. Companies are also looking for various strategies to expand their reach and strengthen their foothold in the marketplace. In January 2018, Lenis Medical and Premier Distributing inked a distribution deal for the sale of its needle-free injection system in the U.S. In March 2018, Namaste Technologies Inc. announced its signing of a non-binding LOI with Inolife R&D Inc., where Namaste holds exclusive rights to research and distribute Inolife's needle-free injection technologies for applications in the cannabis industry.
Lenis Medical and Premier Distributing Form Distribution Deal
Premier Distributing, a division of Premier Media Service Inc. and Lenis Medical Ltd., a developer of patent-pending Lenis needle-free injection system recently inked a distribution agreement for the U.S. sales of the LENIS needle-free injection system. The system is a new generation of needle-free injection that makes use of high-velocity spring loaded mechanical power injecting medications painlessly into the skin. Highly adaptable, the device is applicable to a wide range of subcutaneous and intramuscular medications such as anesthetics, steroids, HA, HGH, HCG, vitamins, insulin, MS Drugs, vaccines, fertility drugs, filers, and orthopedic drugs. LENIS delivers liquid medications by creating a narrow fluid stream which is produced with high-pressure spring power via a micro-orifice at the end of the nozzle, allowing the drug to enter the skin in a fraction of a second and deliver fluids into the body. Made with the titanium components, the device is easy to use in the doctor's office, hospital or at home. Kelly Ryan from Lenis USA said, “We are very excited about the opportunity to bring the needle-free injections to physicians and consumers in the U.S. European diabetics, dentists, veterinarians and aestheticians have had the benefit of such injections for decades, and finally a unique product for patients' comfort, which may improve medication compliance, eliminate hazardous waste and the possibility of accidental needle sticks.”
Namaste Technologies Inc. Signs Non-binding LOI with Inolife R&D Inc.
With an aim to offer innovative products to the medical cannabis market, Namaste Technologies, the largest online retailer for medical cannabis delivery systems signed a non-binding LOI with Inolife R&D Inc., a specialty medical device company. Under the LOI, the former gains the rights to research and distribute the latter’s needle-free injection technologies for use in the cannabis industry. According to Namaste, Inolife's needle-free technologies could revolutionize dosage and administration of cannabis for medical purposes. Namaste hopes to work within the present and future cannabis regulations of Health Canada when initiating the commercialization of pre-filled needle-free syringes.
NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.
SUBMIT YOUR ARTICLE/PROJECT AT editor-in-chief@pharmatutor.org
Subscribe to Pharmatutor Alerts by Email
FIND OUT MORE ARTICLES AT OUR DATABASE
.png)
